[
  {
    "ts": null,
    "headline": "Repay Taps Conduent Executive Houser for CFO Role",
    "summary": "Repay Taps Conduent Executive Houser for CFO Role",
    "url": "https://finnhub.io/api/news?id=b63dcbde4b1afd6a2916d99d09fa1224fa902cb54966166a8e88ade6110e8551",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754933460,
      "headline": "Repay Taps Conduent Executive Houser for CFO Role",
      "id": 136331959,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Repay Taps Conduent Executive Houser for CFO Role",
      "url": "https://finnhub.io/api/news?id=b63dcbde4b1afd6a2916d99d09fa1224fa902cb54966166a8e88ade6110e8551"
    }
  },
  {
    "ts": null,
    "headline": "Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth",
    "summary": "Multiple Myeloma is a cancer affecting plasma cells in bone marrow, often leading to weakened bones, anemia, and kidney damage. The production of abnormal M-proteins is a disease hallmark, detectable in blood or urine. While incurable, treatment advancements like chemotherapy, immunotherapy, and CAR T-cell therapy enhance patient outcomes. Market growth is driven by innovative immunotherapies, yet challenges like high treatment costs, resistance, and late diagnosis persist. Key players such as J",
    "url": "https://finnhub.io/api/news?id=9b792f2d80db8c118ae6948862869b5f26d134d3d1926bdd311f297bfab8402d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754905080,
      "headline": "Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth",
      "id": 136292450,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Multiple Myeloma is a cancer affecting plasma cells in bone marrow, often leading to weakened bones, anemia, and kidney damage. The production of abnormal M-proteins is a disease hallmark, detectable in blood or urine. While incurable, treatment advancements like chemotherapy, immunotherapy, and CAR T-cell therapy enhance patient outcomes. Market growth is driven by innovative immunotherapies, yet challenges like high treatment costs, resistance, and late diagnosis persist. Key players such as J",
      "url": "https://finnhub.io/api/news?id=9b792f2d80db8c118ae6948862869b5f26d134d3d1926bdd311f297bfab8402d"
    }
  },
  {
    "ts": null,
    "headline": "Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations",
    "summary": "The Non-metastatic Prostate Cancer market is witnessing substantial growth driven by increasing demand for targeted therapies and innovative treatment options. Non-metastatic prostate cancer, confined to the prostate gland, benefits from early detection methods like PSA testing and multiparametric MRI, facilitating timely intervention. Key players like Johnson & Johnson, Astellas Pharma, and Pfizer are pioneering advancements with androgen receptor inhibitors and precision medicine. Despite sign",
    "url": "https://finnhub.io/api/news?id=7ed66726fb860b103f275cf311c614095bcaca667705b72b586e98df5fdd96f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754903580,
      "headline": "Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations",
      "id": 136292298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The Non-metastatic Prostate Cancer market is witnessing substantial growth driven by increasing demand for targeted therapies and innovative treatment options. Non-metastatic prostate cancer, confined to the prostate gland, benefits from early detection methods like PSA testing and multiparametric MRI, facilitating timely intervention. Key players like Johnson & Johnson, Astellas Pharma, and Pfizer are pioneering advancements with androgen receptor inhibitors and precision medicine. Despite sign",
      "url": "https://finnhub.io/api/news?id=7ed66726fb860b103f275cf311c614095bcaca667705b72b586e98df5fdd96f9"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.",
    "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
    "url": "https://finnhub.io/api/news?id=4a6b161a97e65ce1a4b104f66d2e62e059f1d1b958b21ca5e5226e3e45801fc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754892000,
      "headline": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.",
      "id": 136294362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
      "url": "https://finnhub.io/api/news?id=4a6b161a97e65ce1a4b104f66d2e62e059f1d1b958b21ca5e5226e3e45801fc7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.",
    "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
    "url": "https://finnhub.io/api/news?id=93bac2fffa27ededc8bd751bb6ba8223840552fe849d03631f0fbd42d95bac1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754892000,
      "headline": "Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.",
      "id": 136292433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
      "url": "https://finnhub.io/api/news?id=93bac2fffa27ededc8bd751bb6ba8223840552fe849d03631f0fbd42d95bac1d"
    }
  }
]